Abstract
Introduction In the CHIPS international randomized trial ”tight” control was of benefit to the mother. It is helpful to predict adverse maternal and perinatal outcomes in women with chronic or gestational hypertension using achieving target blood pressure (BP) levels data. Objectives The aim of our study was to estimate the impact of achieving the target BP less than 140/90 mmHg to 27–28 weeks of gestation on adverse maternal and perinatal outcomes in pregnant women with hypertension. Methods In a prospective cohort study there were included 300 pregnant women: group 1–103 with hypertension without achieving target BP (74 – with chronic hypertension (CH); 29 – with gestational hypertension (GH)); group 2–97 with hypertension who achieved target BP with different antihypertensive drugs (53 – with CH; 44 – with GH); control group – 100 without hypertension. We perfomed clinical examination, genetic investigation using allele-specific polymerase chain reaction (“Lytech”, Russia) collecting data of pregnancy outcomes, statistical analysis (MedCalc ® Version 11.5.0). Results Women without achieving target BP (group 1) were more often had IUGR (14.6% vs 2.0%, p = .002); PE (27.2% vs 3.1%, p p = .06); premature delivery (27.2% vs 3.1%, p p p = .003), preeclampsia during pregnancy (OR 3.68, 95 % CI 1.48–9,16; p = .005) and achievement of target blood pressure less than 140/90 mmHg to 27–28 weeks of gestation (OR 0.12, 95 % CI 0.05–0.28; p Conclusion Achievement of target blood pressure with possible contribution of renin-angiotensin system gene polymorphisms in pregnant women with hypertension to 27–28 weeks of gestation pregnancy may reduce frequency of PE, IUGR, preterm delivery and SGA babies.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call